Literature DB >> 29502864

Hemoptysis? Try Inhaled Tranexamic Acid.

Stephanie Komura1, Robert M Rodriguez2, Christopher R Peabody2.   

Abstract

BACKGROUND: Tranexamic acid (TXA) is a synthetic anti-fibrinolytic agent used to prevent and treat various bleeding complications. In many studies, investigators have evaluated its utility and safety orally, intravenously, and topically, but few studies have described the potential benefits of nebulized TXA. CASE REPORT: We present a case of massive hemoptysis treated with nebulized TXA in the emergency department (ED) that led to the cessation of bleeding and avoidance of endotracheal intubation. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: In massive hemoptysis, rapidly available nebulized TXA may be considered a therapeutic option, serving either as primary therapy or as a bridge until other definitive therapies can be arranged.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  hemoptysis treatment; massive hemoptysis; nebulized tranexamic acid; tranexamic acid

Mesh:

Substances:

Year:  2018        PMID: 29502864     DOI: 10.1016/j.jemermed.2018.01.029

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  3 in total

1.  Use of intrapulmonary administration of thrombin in hematological malignancy patients with alveolar haemorrhage: A case series.

Authors:  Jongmin Lee; Chin Kook Rhee; Seok Chan Kim; Young Kyoon Kim; Hee Je Kim; Seok Lee; Seok-Goo Cho; Jong Wook Lee
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

2.  Inhaled Tranexamic Acid As a Novel Treatment for Pulmonary Hemorrhage in Critically Ill Pediatric Patients: An Observational Study.

Authors:  Erika R O'Neil; Lindsay R Schmees; Karla Resendiz; Henri Justino; Marc M Anders
Journal:  Crit Care Explor       Date:  2020-01-29

3.  A Case Report of Nebulized Tranexamic Acid for Post-tonsillectomy Hemorrhage in an Adult.

Authors:  Michael Poppe; Felipe Grimaldo
Journal:  Clin Pract Cases Emerg Med       Date:  2020-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.